Paper39337273
Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle.
Scellini B and 6 others. Int J Mol Sci, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle. Papers, record 39337273. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39337273
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Urea | Major topic |
| Myofibrils | Major topic |
| Myocardial Contraction | Major topic |
| Humans | |
| Calcium | |
| Myocardium | |
| Protein Isoforms | |
| Myosins | |
| Heart Ventricles | |
| Male | |
| Cardiac Myosins | |
| Female | |
| Adult |
Source PubMed
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27012405 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. | J Am Coll Cardiol | 2016 | https://conductscience.org/library/papers/27012405 | PubMed |
| 2 | 10827985 | The effect of inorganic phosphate on force generation in single myofibrils from rabbit skeletal muscle. | Biophys J | 2000 | https://conductscience.org/library/papers/10827985 | PubMed |
| 3 | 18617566 | Phosphate metabolite concentrations and ATP hydrolysis potential in normal and ischaemic hearts. | J Physiol | 2008 | https://conductscience.org/library/papers/18617566 | PubMed |
| 4 | 35534374 | Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. | Eur J Intern Med | 2022 | https://conductscience.org/library/papers/35534374 | PubMed |
| 5 | 35852543 | Omecamtiv Mecarbil as a Therapy for Heart Failure With Low Ejection Fraction. | JAMA | 2022 | https://conductscience.org/library/papers/35852543 | PubMed |
| 6 | 21415352 | Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. | Science | 2011 | https://conductscience.org/library/papers/21415352 | PubMed |
| 7 | 26140433 | The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat. | Br J Pharmacol | 2015 | https://conductscience.org/library/papers/26140433 | PubMed |
| 8 | 38566963 | Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/38566963 | PubMed |
| 9 | 30242219 | Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. | Nat Commun | 2018 | https://conductscience.org/library/papers/30242219 | PubMed |
| 10 | 21856480 | Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. | Lancet | 2011 | https://conductscience.org/library/papers/21856480 | PubMed |
| 11 | 33891673 | Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle. | J Gen Physiol | 2021 | https://conductscience.org/library/papers/33891673 | PubMed |
| 12 | 15621050 | Myocardial contraction is 5-fold more economical in ventricular than in atrial human tissue. | Cardiovasc Res | 2005 | https://conductscience.org/library/papers/15621050 | PubMed |
| 13 | 2966401 | Effect of Ca2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. | Proc Natl Acad Sci U S A | 1988 | https://conductscience.org/library/papers/2966401 | PubMed |
| 14 | 24878771 | Sex differences in myosin heavy chain isoforms of human failing and nonfailing atria. | Am J Physiol Heart Circ Physiol | 2014 | https://conductscience.org/library/papers/24878771 | PubMed |
| 15 | 34704115 | Alpha and beta myosin isoforms and human atrial and ventricular contraction. | Cell Mol Life Sci | 2021 | https://conductscience.org/library/papers/34704115 | PubMed |
| 16 | 9530220 | Electrophoretic separation and quantitation of cardiac myosin heavy chain isoforms in eight mammalian species. | Am J Physiol | 1998 | https://conductscience.org/library/papers/9530220 | PubMed |
| 17 | 26246073 | Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity. | Nat Commun | 2015 | https://conductscience.org/library/papers/26246073 | PubMed |
| 18 | 31103235 | Omecamtiv Mecarbil Slows Myosin Kinetics in Skinned Rat Myocardium at Physiological Temperature. | Biophys J | 2019 | https://conductscience.org/library/papers/31103235 | PubMed |
| 19 | 8307894 | Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. | J Appl Physiol (1985) | 1993 | https://conductscience.org/library/papers/8307894 | PubMed |
| 20 | 35852527 | Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. | JAMA | 2022 | https://conductscience.org/library/papers/35852527 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42289718 | Targeting cardiac myosin in HFrEF: mechanism, clinical evidence, and the role of omecamtiv mecarbil. | J Cardiothorac Surg | 2026 | https://conductscience.org/library/papers/42289718 | PubMed |
| 41858918 | Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/41858918 | PubMed |
| 40313875 | Mechanistic insights into effects of the cardiac myosin activator omecamtiv mecarbil from mechanokinetic modelling. | Front Physiol | 2025 | https://conductscience.org/library/papers/40313875 | PubMed |
| 40142759 | Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice. | J Clin Med | 2025 | https://conductscience.org/library/papers/40142759 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MYH14 | 79784 | PubTator's text mining | https://conductscience.org/library/genes/79784 | NCBI Gene |
| MYH6 | 4624 | PubTator's text mining | https://conductscience.org/library/genes/4624 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39337273
GET https://conductscience.org/api/papers/v1/39337273/references?page=2